XORTX Therapeutics Inc. (XRTX) Stock Analysis

Company Overview

XORTX Therapeutics Inc. (XRTX) is capitalised at $4.20M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry.

The most recent close on file for XRTX is $2.31, dated September 4, 2026. That is +$0.16 (+7.44%) against the previous close. Over the past 52 weeks the price has ranged from $1.73 to $7.05. The latest close sits 33.91% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $2.66M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −2.58.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 2.88.

Beta against the wider market is reported at 0.44. Daily returns over the trailing 5 years annualize to a volatility of 143.23%. Over the trailing twelve months the price has returned −42.96%. Across 5 years the annualized return works out at −74.22%.

Growth & Income

The record shows no dividend for XRTX.

2026 is still running; the price is −17.79% year to date. Across the complete calendar years on file, 2025 returned −50.27% and 2023 returned −96.47%. Of the 4 complete calendar years on file, 0 finished higher.